Article
Oncology
Soufyan Annakib, Valerie Rigau, Amelie Darlix, Catherine Goze, Hugues Duffau, Luc Bauchet, Marta Jarlier, Michel Fabbro
Summary: This study retrospectively evaluated the clinical outcomes of bevacizumab as rescue treatment for recurrent WHO grades II-III glioma, and found that bevacizumab displayed prolonged activity in a subset of patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Article
Radiology, Nuclear Medicine & Medical Imaging
Beatrice Detti, Silvia Scoccianti, Maria Ausilia Teriaca, Virginia Maragna, Victoria Lorenzetti, Sara Lucidi, Chiara Bellini, Daniela Greto, Isacco Desideri, Lorenzo Livi
Summary: Overall, the analysis confirms the efficacy of bevacizumab in patients with recurrent high-grade gliomas, with an acceptable toxicity profile. The study found that performance status, age at diagnosis, and the use of corticosteroids during bevacizumab therapy were strongly associated with progression-free survival. Long-term responders accounted for more than half of the cohort.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ryo Kurokawa, Akifumi Hagiwara, Mariko Kurokawa, Benjamin M. M. Ellingson, Akira Baba, Toshio Moritani
Summary: This study explored the ability of whole tumor ADC histogram profiles to differentiate between the presence and absence of grade 4 molecular features in histologically lower-grade gliomas. The results showed that the entropy of ADC histogram and age at diagnosis were independent predictive parameters, which could serve as potential imaging biomarkers for predicting grade 4 gliomas.
EUROPEAN RADIOLOGY
(2023)
Review
Clinical Neurology
Daniel P. Kulinich, John P. Sheppard, Thien Nguyen, Aditya M. Kondajji, Ansley Unterberger, Courtney Duong, Adam Enomoto, Kunal Patel, Isaac Yang
Summary: The combination of re-irradiation therapy (reRT) and bevacizumab (BVZ) therapy may improve overall survival (OS) and reduce rates of radiation necrosis (RN) in recurrent high-grade gliomas (HGG) patients. However, further controlled studies are needed to confirm these effects.
ACTA NEUROCHIRURGICA
(2021)
Article
Oncology
Karan S. Dixit, Sean Sachdev, Christina Amidei, Priya Kumthekar, Tim J. Kruser, Vinai Gondi, Sean Grimm, Rimas Lukas, Martin Kelly Nicholas, Steven J. Chmura, Angela J. Fought, Minesh Mehta, Jeffrey J. Raizer
Summary: This study demonstrates that re-irradiation with bevacizumab and temozolomide is a safe and effective salvage treatment for patients with bevacizumab-refractory high-grade glioma. Patients further from their initial radiotherapy may derive greater benefit from this regimen.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Solmaz Sahebjam, Peter A. Forsyth, Nam D. Tran, John A. Arrington, Robert Macaulay, Arnold B. Etame, Christine M. Walko, Theresa Boyle, Edwin N. Peguero, Michael Jaglal, Sepideh Mokhtari, Heiko Enderling, Natarajan Raghunand, Tyra Gatewood, Wendy Long, Jennifer L. Dzierzeski, Brittany Evernden, Timothy Robinson, Melissa C. Wicklund, Sungjune Kim, Zachary J. Thompson, Dung-Tsa Chen, Prakash Chinnaiyan, Hsiang-Hsuan Michael Yu
Summary: The combination of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab is generally safe and well tolerated in patients with recurrent high-grade gliomas. In patients without prior bevacizumab treatment, 83% showed complete or partial response, while in bevacizumab-resistant patients, 62% achieved partial response. This treatment approach warrants further investigation for its potential in improving outcomes for high-grade glioma patients.
Article
Oncology
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Lindeman, Olivia Campagne, Anu Banerjee, Sridharan Gururangan, Lindsay B. Kilburn, Stewart Goldman, Ibrahim Qaddoumi, Patricia Baxter, Gilbert Vezina, Corey Bregman, Zoltan Patay, Jeremy Y. Jones, Clinton F. Stewart, Michael J. Fisher, Laurence Austin Doyle, Malcolm Smith, Ira J. Dunkel, Maryam Fouladi
Summary: This study presented the results of treating children with recurrent/progressive OPHGs using selumetinib in a PBTC phase II trial. The treatment resulted in partial responses in 24% of patients, stable disease in 56%, and disease progression in 20%, with a median number of 26 treatment courses. The two-year PFS was 78%, and evaluation of visual acuity showed improvement and stability in a portion of patients.
Article
Oncology
Megan Mantica, Jan Drappatz, Frank Lieberman, Constantinos G. G. Hadjipanayis, L. Dade Lunsford, Ajay Niranjan
Summary: The purpose of this study was to evaluate the overall survival (OS) in patients with recurrent glioblastoma (GBM) treated with Border Zone SRS plus bevacizumab. The results showed that there was no significant difference in survival between the BZ-SRS group and the institutional historical controls. However, secondary analysis revealed a trend towards improved 6-month progression-free survival (PFS-6).
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Roberta Carbonara, Letizia Laera, Maria Paola Ciliberti, Maria Annunziata Gentile, Morena Caliandro, Nicola Sasso, Ilaria Bonaparte, Vincenzo Fanelli, Romina Tortora, Eleonora Paulicelli, Giammarco Surico, Giuseppe Lombardi, Francesco Signorelli, Alba Fiorentino
Summary: The study evaluated the safety and efficacy of re-irradiation with radiosurgery or fractionated stereotactic radiotherapy in association with chemotherapy for recurrent high-grade gliomas. The results demonstrated that this treatment approach is safe and feasible for patients with recurrent HGG.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Clinical Neurology
Christina M. Flies, Tom J. Snijders, Tom Van Seeters, Marion Smits, Filip Y. F. De Vos, Jeroen Hendrikse, Jan Willem Dankbaar
Summary: The study found that perfusion imaging with ASL-MRI can predict malignant progression within 12 months in patients with grade II glioma.
Article
Oncology
Kosuke Aoki, Hiromichi Suzuki, Takashi Yamamoto, Kimiyo N. Yamamoto, Sachi Maeda, Yusuke Okuno, Melissa Ranjit, Kazuya Motomura, Fumiharu Ohka, Kuniaki Tanahashi, Masaki Hirano, Tomohide Nishikawa, Hiroyuki Shimizu, Yotaro Kitano, Junya Yamaguchi, Shintaro Yamazaki, Hideo Nakamura, Masamichi Takahashi, Yoshitaka Narita, Mitsutoshi Nakada, Shoichi Deguchi, Masahiro Mizoguchi, Yasutomo Momii, Yoshihiro Muragaki, Tatsuya Abe, Jiro Akimoto, Toshihiko Wakabayashi, Ryuta Saito, Seishi Ogawa, Hiroshi Haeno, Atsushi Natsume
Summary: This study used a mathematical model to uncover therapeutic strategies for IDHmutLGGs and identified precision medicine approaches based on different genetic alterations. It highlighted the importance of prompt adjuvant chemoradiotherapy for small IDHmut-LGGs and the differential treatment needs for large IDHmut-LGGs based on genetic subtypes.
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Katherine Green, Paraskevi Panagopoulou, Felice D'Arco, Patricia O'Hare, Richard Bowman, Bronwen Walters, Christine Dahl, Mette Jorgensen, Pritesh Patel, Olga Slater, Rehana Ahmed, Simon Bailey, Fernando Carceller, Rhiannon Collins, Elizabeth Corley, Martin English, Lisa Howells, Ahmed Kamal, John-Paul J. P. Kilday, Stephen Lowis, Blanche Lumb, Erika Pace, Susan Picton, Barry Pizer, Ayad Shafiq, Lena Uzunova, Harriet Wayman, Shaun Wilson, Darren Hargrave, Enrico Opocher
Summary: A nationwide UK service evaluation on the use of bevacizumab in children with pediatric low-grade glioma (PLGG) showed that it can effectively control short-term progression of PLGG and significantly improve visual outcomes. However, there are potential toxicities and risks of further progression, highlighting the need for further research to optimize the treatment strategy of bevacizumab.
Article
Oncology
Christina I. Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, Martha M. Matuszak, Enrico C. Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John T. Hamm, Kevin S. Oh, Arif N. Ali, Michelle M. Kim, Scott M. Lindhorst, Minesh P. Mehta
Summary: This study evaluated whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS) compared to BEV alone in recurrent glioblastoma (GBM). The results showed that the combination of re-RT and BEV significantly improved PFS, but had no difference in OS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Eric S. Lipp, Patrick Healy, Alan Austin, Alysha Clark, Tara Dalton, Kathryn Perkinson, James E. Herndon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Roger E. McLendon
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
(2019)
Correction
Immunology
Vesteinn Thorsson, David L. Gibbs, Scott D. Brown, Denise Wolf, Dante S. Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F. Gao, Christopher L. Plaisier, James A. Eddy, Elad Ziv, Aedin C. Culhane, Evan O. Paull, I. K. Ashok Sivakumar, Andrew J. Gentles, Raunaq Malhotra, Farshad Farshidfar, Antonio Colaprico, Joel S. Parker, Lisle E. Mose, Nam Sy Vo, Jianfang Liu, Yuexin Liu, Janet Rader, Varsha Dhankani, Sheila M. Reynolds, Reanne Bowlby, Andrea Califano, Andrew D. Cherniack, Dimitris Anastassiou, Davide Bedognetti, Younes Mokrab, Aaron M. Newman, Arvind Rao, Ken Chen, Alexander Krasnitz, Hai Hu, Tathiane M. Malta, Houtan Noushmehr, Chandra Sekhar Pedamallu, Susan Bullman, Akinyemi I. Ojesina, Andrew Lamb, Wanding Zhou, Hui Shen, Toni K. Choueiri, John N. Weinstein, Justin Guinney, Joel Saltz, Robert A. Holt, Charles S. Rabkin, Alexander J. Lazar, Jonathan S. Serody, Elizabeth G. Demicco, Mary L. Disis, Benjamin G. Vincent, Ilya Shmulevich
Article
Oncology
Mallika P. Patel, Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, Frances McSherry, Eric S. Lipp, Elizabeth Miller, Katherine B. Peters, Mary Lou Affronti
SUPPORTIVE CARE IN CANCER
(2020)
Article
Clinical Neurology
Christian Thomas, Annika Wefers, Susanne Bens, Karolina Nemes, Abbas Agaimy, Florian Oyen, Silke Vogelgesang, Fausto J. Rodriguez, Francesca M. Brett, Roger McLendon, Istvan Bodi, Fanny Burel-Vandenbos, Kathy Keyvani, Stefan Tippelt, Frantz R. Poulsen, Eric S. Lipp, Caterina Giannini, Guido Reifenberger, Klaus Kuchelmeister, Torsten Pietsch, Uwe Kordes, Reiner Siebert, Michael C. Fruehwald, Pascal D. Johann, Martin Sill, Marcel Kool, Andreas von Deimling, Werner Paulus, Martin Hasselblatt
ACTA NEUROPATHOLOGICA
(2020)
Article
Oncology
Mallika P. Patel, John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters
JOURNAL OF NEURO-ONCOLOGY
(2020)
Article
Oncology
Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, Mustafa Khasraw
CLINICAL CANCER RESEARCH
(2020)
Article
Multidisciplinary Sciences
Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. Varn, Roel G. Verhaak, Junfei Zhao, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, Frances McSherry, Andrea M. Muscat, Eric S. Lipp, Smita K. Nair, Mustafa Khasraw, Katherine B. Peters, Dina Randazzo, John H. Sampson, Roger E. McLendon, Darell D. Bigner, David M. Ashley
Summary: The study found that low tumor mutation burden is associated with longer survival after immunotherapy in recurrent glioblastoma patients, and this relationship is related to inflammatory gene signatures, which evolves upon recurrence.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Jessica W. Lee, John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters, Margaret O. Johnson
Summary: In this study of older patients with GBM, age and KPS were associated with the choice between short-course and standard RT. Both regimens showed similar overall survival, but some patients experienced worsening symptoms and discontinued treatment during RT. Further research into predictors of RT completion and survival could help improve adjuvant therapy and supportive care for older patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Katherine B. Peters, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, Maria W. Freeman, Dina M. Randazzo, Annick Desjardins, Henry S. Friedman
Summary: A placebo-controlled, double-blind study showed that low-dose naltrexone (LDN) did not have a significant impact on quality of life and fatigue in patients with high-grade glioma (HGG) during concurrent chemotherapy and radiation therapy.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Clinical Neurology
Mallika P. Patel, Eric S. Lipp, Elizabeth S. Miller, Patrick N. Healy, James E. Herndon, Katherine B. Peters
Summary: The study found that most clinical members in the surveyed neuro-oncology community do not have the support or expertise of dedicated neuro-oncology pharmacists, despite the demanding nature of their outpatient practices.
NEURO-ONCOLOGY PRACTICE
(2022)
Article
Clinical Neurology
Alexander Yuile, Mustafa Khasraw, Justin T. Low, Kyle M. Walsh, Eric Lipp, Joanne Sy, Laveniya Satgunaseelan, Marina Ann Kastelan, Madhawa De Silva, Adrian Lee, Helen Wheeler
Summary: This study investigates the current patterns of clinical practice for histone mutant gliomas (HMG) in Australia and the United States (US). The results show variations in testing methods and treatment approaches for HMG patients, and the knowledge of H3 mutations impacts the management of these gliomas, particularly during recurrence.
NEURO-ONCOLOGY PRACTICE
(2022)
Article
Hematology
Kirsten Bell Burdett, Dusten Unruh, Michael Drumm, Alicia Steffens, Jonathan Lamano, Jonathan Judkins, Margaret Schwartz, Rodrigo Javier, Christina Amidei, Eric S. Lipp, Katherine B. Peters, Albert Lai, Blaine S. C. Eldred, Amy B. Heimberger, Kathleen McCortney, Denise M. Scholtens, Craig Horbinski
Summary: The study developed a VTE prediction tool to improve care for adult-type diffuse glioma patients, incorporating clinical, blood-based, histologic, and molecular markers. Analysis of data from 258 newly diagnosed patients revealed that tumor expression of TF and PDPN correlated with VTE, and circulating TF and D-dimers correlated with VTE risk. Several factors, including past VTE history, hypertension, asthma, white blood cell count, WHO tumor grade, patient age, and body mass index, predicted increased VTE risk in newly diagnosed glioma patients. Conversely, IDH mutation, hypothyroidism, and MGMT promoter methylation predicted reduced VTE risk.
Article
Oncology
Emily Hanzlik, Bridget Archambault, Mays El-Dairi, Kristin Schroeder, Mallika P. Patel, Eric S. Lipp, Katherine B. Peters, David M. Ashley, Daniel Landi
Summary: A retrospective chart review showed that trametinib is effective and well-tolerated in patients with progressive low-grade glioma. The best radiographic response was seen after a longer duration of therapy, and patients with optic pathway lesions showed stable to improved vision while on treatment.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
(2023)
Article
Clinical Neurology
Dina M. Randazzo, Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, Patrick Healy, Jennifer Jackman, Brian Crouch, Annick Desjardins, David M. Ashley, Henry S. Friedman, Katherine B. Peters
Summary: This study aimed to investigate the association between spiritual well-being (SWB) and health-related quality of life (HRQoL) in primary brain tumor patients. The results showed that higher SWB was associated with better HRQoL, emphasizing the importance of spiritual aspects in strategies to improve HRQoL in primary brain tumor patients.
NEURO-ONCOLOGY PRACTICE
(2021)
Letter
Oncology
Erica Shen, Margaret O. Johnson, Jessica W. Lee, Eric S. Lipp, Dina M. Randazzo, Annick Desjardins, Roger E. McLendon, Henry S. Friedman, David M. Ashley, John P. Kirkpatrick, Katherine B. Peters, Kyle M. Walsh
NEURO-ONCOLOGY ADVANCES
(2019)